J&J’s Drug Pipeline Not Strong Enough to Accelerate Growth

Increasing commotion over its branded drugs and a device segment that seems to lack innovation will hold back J&J’s revenue growth in the coming years.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.